Preparation, pharmacokinetic and pharmacodynamic evaluation of carbamazepine inclusion complexes with cyclodextrins

S.T.P. Pharma Sciences

Volumn 12, Issue 6, 2002, Pages 369-378

  El Gindy, G A ^a   Mohammed, F A ^a   Salem, S Y ^a  

^a Assiut University   (Egypt)

Author keywords

CD; CD; Bioavailability and anti convulsion activity; Carbamazepine; Dissolution; DM CD; DSC; Inclusion complexes; IR spectroscopy; Solubility; X ray diffraction

Indexed keywords

ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; CARBAMAZEPINE; CYCLODEXTRIN; DI O METHYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; INFRARED SPECTROMETRY; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; X RAY DIFFRACTION;

EID: 0036857995     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. th Ed., Pharmaceutical Press, London, 1993, pp. 295-298.
2. nd Ed., The Pharmaceutical Press, London, 1986.
3. Riad L.E., Chan K.K., Wagner W.E. - Simultaneous first and zero-order absorption of carbamazepine tablets in human. - J. Pharm. Sci., 75, 897-900, 1986.
4. Hartley R., Aleksandrowicz L., Bowmerc J., Cavood A., Forsythe W.J. - Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy. - J. Pharm. Pharmacol., 43, 117-119, 1991.
5. Chan K.K.H., Sawchuck R.J., Thompson T.A., Redajin E., Wagner W.E., Lesher R.R., Weeks B., Hall N.R., Gerordin A. - Bioequivalence of carbamazepine chewable tablets: Single dose and steady state studies. - J. Pharm. Sci., 74, 866-870, 1980.
6. Mayer M.C., Straughn B.A., Jarvi E.J., Wood G.C., Pelsos F.R., Shah V.P. - The bioequivalence of carbamazepine tablets with a history of clinical failure. - Pharm. Res., 9, 1612-1616, 1992.
7. Morselli P.L., Monaco F., Gerna M., Recchia M., Riccio A. - Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients. - Epilepsia, 16, 759-764, 1975.
8. Ball T.W., Schleifer L.S. - Drugs effective in the therapy of the epilepsies. - In: The Pharmacological Basis of Therapeutics, M. Goodman, B. Gilman Eds., 7th ed., Macmillan, New York, 1985, pp. 446-472.
9. Cohen J., Lach J.L. - Interaction of pharmaceuticals with Scardinger dextrins. I. Interaction with hydrobenzoic acids and p-hydroxybenzoates. - J. Pharm. Sci., 52, 132, 1963.
10. Duchene D., Wouessidjewe D. - Pharmaceutical uses of cyclodextrins and derivatives. - Drug Dev. Ind. Pharm., 15, 2487-2499, 1990.
11. Loftsson T., Frioriksdottir B.J. - Solubilization and stabilization of drugs through cyclodextrin complexation. - Acta Pharm. Nord., 3, 215-217, 1991.
12. Haller B.W., Brauns U. - Solubilization of drugs by modified β-cyclodextrins. - Int. J. Pharm., 26, 77-88, 1985.
13. Londhe V. Y., Nagarsenkar M.S. - Solid dispersions of hydroxypropyl-beta-cyclodextrin and carbamazepine: Study of complexation and in vitro dissolution profile. - Indian Drugs, 36, 12-20, 1999.
14. El-zein H., Riad L., El-Bary A.A. - Enhancement of carbamazepine dissolution: In vitro and in vivo evaluation. - Int. J. Pharm., 168, 209-220, 1998.
15. Nagarsenker M.S., Bhave V.M. - Kneaded solid dispersions of hydroxypropyl-beta-cyclodextrin and carbamazepine: Complexation and in vitro dissolution profile. - Pharm. Pharmacol. Comm., 4, 335-338, 1998.
16. Loftsson T., Frioriksdottir H. - Effect of water-soluble polymers on the aqueous solubility and complexing abilities of beta-cyclodextrin. - Int. J. Pharm., 163, 115-121, 1998.
17. El-Nahhas S.A. - Physicochemical characteristics of carbamazepine-beta-cyclodextrin inclusion compounds and carbamazepine-PEG solid dispersions. - Pharmazie, 51, 960963, 1996.
18. Brewster M.E., Anderson W.R., Meinsma D., Moreno D., Pop E. - Intravenous and oral pharmacokinetic evaluation of 2-hydroxypropyl-beta-cyclodextrin based formulation of carbamazepine in the dog: Comparison with commercially available tablets and suspensions. - J. Pharm. Sci., 86, 335-339, 1997.
19. Cheung B.W., Wang Y., Brewster M.E., Sawchuk R.J. - Brain delivery of carbamazepine during intravenous administration of polyethylene glycol and 2-hydroxypropylbeta-cyclodextrin formulations. - STP Pharma Sci., 7, 78-84, 1997.
20. Al-Meshal M.A., El-Mahrook G.M., Al-Angary A.A., Gouda M. W. - Interaction of carbamazepine with cyclodextrins. - Pharm. Ind., 55, 1129-1132, 1993.
21. Hoshino T., Uekama K., Pitha J. - Increase in temperature enhances solubility of drugs in aqueous solutions of hydroxypropyl-beta-cyclodextrins. - Int. J. Pharm., 98,239-242, 1993.
22. Bettach C.J., Gonzalez M.A., McHiernan B.C., Neff-Davis C., Bodor N. - Oral pharmacokinetics of carbamazepine: In dogs from commercial tablets and a cyclodextrin complex. J. Pharm. Sci., 82, 1058-1060, 1993.
23. Choudhury S., Nelson K.F. - Improvement of oral bioavailability of carbamazepine by inclusion in 2-hydroxypropylbeta-cyclodextrin. - Int. J. Pharm., 85, 175-180, 1992.
24. Brewster M.E., Anderson W.R., Estes K.S., Bodor N. - Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins. - J. Pharm. Sci., 80, 380-383, 1991.
25. Higuchi T., Conners K.A. - Phase solubility techniques. - in: Advance in Analytical Chemistry Instrumentation, Interscience Publisher, New York, 1965, pp. 117-212.
26. Chan K.K.H. - Simultaneous determination of carbamazepine and its epixide metabolite in plasma and urine by high performance liquid chromatography. - J. Chromatogr., 342, 341-346, 1985.
27. Niazl S. - Textbook of Biopharmaceutics and Clinical Pharmacokinetics. - Appleloncentury Crofts, New York, 1979, pp. 57-60.
28. th Ed., Iowa State University Press, 1989.
29. Kent A.P., Webster R.A. - The evaluation of different types of anti-convulsant drug activity against leptazol-induced epileptogenic activity in the anaesthetized rat. - Br. J. Pharmacol., 78, 553-559, 1983.
30. Chambon J., Brochard J., Hallot A., Heaulme M., Brodin R. - A structurally novel anticonvulsant in mice, rats and baboons. - J. Pharmacol. Exp. Therapeutics, 233 (3), 836-844, 1985.
31. Poisson M., Huguet A., Bakri-Logeais F., Narcisse G. - A new type of anticonvulsant, Stiripentol: Pharmacological profile and neurochemical study. - Drug Res., 34 (1), No. 2, 1984.
32. Woodbury D.M. - Convulsant drugs: Mechanisms of action. - Adv. Neurol., 27, 249-303, 1980.
33. Reinhard J.F., Reinhard J.F. Jr. - Experimental evaluation of anticonvulsants. - In: Anticonvulsants, J.A. Vida Ed., Academic Press, New York, 1977, pp. 581112.
34. Litcfield, J.T. Jr., Wilcoxon F. - A simplified method of evaluating dose-effect experiments. - J. Pharmacol. Exp. Ther., 96, 99-113, 1994.
35. nd ed., Raven Press, New York, 1982, pp. 111-126.